Angel Physicians Fund
VC Fund
Angel Physicians Fund is a seed investor comprising of doctors and medical pioneers who are solely reliant on bioscience and health funds.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Angel Physicians Fund invests in
Stages Angel Physicians Fund invests in
Countries Angel Physicians Fund invests in
Investment Focus
Industry
- Medical Device 6 (67%)
- Health Care 5 (56%)
- Therapeutics 4 (44%)
- Medical 3 (33%)
- Biotechnology 2 (22%)
Stage
- Series A 4 (44%)
- Seed 2 (22%)
- Series B 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CardioRenal Systems
|
CardioRenal Systems is a medical device company that develops and markets the RenalPro system, also branded as RenalGuard outside the United States, for renal protection and fluid balance management. The RenalPro Therapy system combines a console and single-use infusion and urine collection sets to automate matched hydration in response toreal-time urine output. Its core function is to adjust intravenous fluid administration in milliliter increments to maintain hemodynamic stability and avoid over- or under-hydration. The technology is used to support prevention of acute kidney injury in settings such as cardiac surgery, contrast-associated procedures in the cath lab, and intensive care. CardioRenal Systems also provides clinical documentation, operating manuals, and supports clinical studies evaluating RenalPro-based therapies. | Jul 07, 2026 | |
Alphyn Biologics
|
Alphyn Biologics is a life science company that develops proprietary drug therapy for treating skin diseases. Alphyn's initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on their proprietary Multi-Target Therapeutic (MTT) plant-derived technology platform. | $25M / Series B / Dec 12, 2025 | |
Cordance Medical
|
Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases. | $8M / Seed / Nov 24, 2025 | |
|
Alphyn Biologics
|
Alphyn Biologics is a life science company that develops proprietary drug therapy for treating skin diseases. Alphyn's initial target indication are skin infections caused by deadly drug-resistant MRSA bacteria based on their proprietary Multi-Target Therapeutic (MTT) plant-derived technology platform. | $3.3M / Series A / Sep 15, 2022 | |
PanTher Therapeutics
|
PanTher Therapeutics is on a mission to revolutionize cancer care with a proprietary treatment platform designed to enhance therapeutic response with minimal side effects. PanTher’s highly adaptable platform empowers oncologists to treat patients with life-threatening cancer by unlocking a drug’s full potential through direct, sustained treatmentat the tumor site. This distinctive targeting capability uniquely positions PanTher to take on the deadliest and most difficult to treat cancers with a lead investigational candidate in pancreatic cancer. | $5.4M / Series A / May 19, 2021 | |
Elucid
|
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from asingle CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services. | $10M / Series A / May 10, 2021 | |
Moray Medical
|
Moray Medical develops a structural heart robotic delivery systems for edge-to-edge valve leaflet repair.Moray Medical is working to improve the quality of life for the millions suffering from leaky heart valves. Using our proprietary microfluidic robotics, more cardiologists can safely and cost-effectively treat the large number of patients whoneed mitral valve clip therapies. | $5.7M / Seed / Apr 12, 2021 | |
S4 Medical
|
Sotera is a medical device company focused on innovative solutions for cardiac procedures. The company’s initial product is a solution for reducing complications to the esophagus during catheter ablation treatment for atrial fibrillation.It is commercializing a novel medical device designed to protect the esophagus during catheter ablationprocedures. | $3M / Series A / Apr 02, 2021 | |
Foldax
|
Foldax is developing synthetic heart valves with the goal of delivering non-thrombogenic aortic and mitral valves at dramatically lower costs to existing artificial or tissue valves. It operates in the manufacturing sector. The company was incorporated in 2013 and is based in Salt Lake City, Utah. | $20M / Series D / Jun 22, 2020 |
Co-Investors
QCA Ventures
2 deals together
415 Capital
1 deal together
BioStar Capital
1 deal together
Bioverge
1 deal together
BlueStone Venture Partners
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Angel Physicians Fund invest in?
Angel Physicians Fund invests primarily in Medical Device, Health Care and Therapeutics startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Angel Physicians Fund last invest?
The most recent investment recorded for Angel Physicians Fund closed in Jul 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
